英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
cingulate查看　cingulate　在百度字典中的解释百度英翻中〔查看〕
cingulate查看　cingulate　在Google字典中的解释Google英翻中〔查看〕
cingulate查看　cingulate　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Cingulate Inc
    Cingulate Inc provides information for stockholders, potential investors, and financial analysts about its business and financial performance
  • Cingulate Reports Safety Results from Final Phase 3 Trials for Lead . . .
    Cingulate’s lead candidate, CTx-1301, utilizes Cingulate’s proprietary PTR drug delivery platform to create a breakthrough, multi-core formulation of the active pharmaceutical ingredient dexmethylphenidate, a compound approved by the FDA for the treatment of ADHD
  • Cingulate® Technology - Cingulate Inc
    Cingulate is developing ADHD medications capable of achieving precise once-daily dosing using a novel erosion based controlled release technology that provides unrivaled control of drug release
  • CTx-1301 - Cingulate Inc
    CTx-1301 utilizes Cingulate’s innovative Precision Timed Release™ (PTR™) drug delivery platform technology to create a breakthrough multi-core formulation of dexmethylphenidate, a compound approved by the FDA for the treatment of ADHD
  • Cingulate Inc. Reports Third Quarter 2023 Financial Results and . . .
    Cingulate commenced the pivotal Phase 3 fixed-dose pediatric and adolescent safety and efficacy study in late July 2023 and a Phase 3 pediatric dose-optimization onset and duration study in early August 2023, with results expected in the first half of 2024
  • Cingulate Completes Financing Transaction for Net Proceeds of . . .
    With an initial focus on the treatment of ADHD, Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders
  • SEC Filings - Cingulate Inc
    Cingulate Inc Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
  • Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its . . .
    With an initial focus on the treatment of ADHD, Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders
  • 0001641172-25-000970 - 10-K - Cingulate Inc
    Cingulate® Technology; Publications; CTx-1301: ADHD; CTx-1302: ADHD; CTX-2103: Anxiety
  • Form 10-Q for Cingulate INC filed 05 08 2025
    Cingulate Inc (E xac t n ame of re gi s tr an t as s p e c i fi e d i n i ts c h ar te r ) D e l aw are 86-3825535 (State or other jurisdiction of incorporation or organization) (I R S Employer Identification No ) 1901 W 47 th P l ac e K an s as C i ty, K S 66205 (Address of principal executive offices) (Zip Code) (913) 942-2300





中文字典-英文字典  2005-2009